Pre COVID-19 pandemic no one could have imagined a pandemic of such magnitude could happen across the globe bringing the world to a halt. Evidently, the current sanitary situation and travelling restrictions across continents has brought onsite audits to a standstill. However, the qualification process cannot be compromised so what options do pharma companies have…
Some of the requirements to conduct on-site GMP audits are therefore clear, for example in Article 46(f) EU Directive 2001/83/EC:
“the holder of the manufacturing authorisation shall verify compliance by the manufacturer and distributors of active substances with good manufacturing practice and good distribution practices by conducting audits at the manufacturing and distribution sites…”
Some of the options incorporated by the authorities or even the marketing authorisation holders is to have a distant assessment through remote desktop audits either through video conferencing or an audio communication. In April 2020 the EMEA authorities have already devised a questionnaire (question and answer document) which broadly addresses the remote distant assessment of manufacturer’s and cites examples of audits which can be conducted.
The pharmaceutical industry and marketing authorisation holders have little choice but to resort to remote desktop GMP verification. A distant assessment is therefore a possible way to assess manufacturer’s or CMO’s GMP compliance. The Qualified Person (QP) conducting desktop audit can clearly point out that distant assessments are not intended as a substitute for on-site inspections and that on-site inspections should be carried out as soon as circumstances permit. Decision should be based on an adequate, scientific and documented risk assessment.
For new sites too such distant assessments by the competent authorities can be an option and provisional GMP certificate can be issued based on the assessment outcome with a condition to allow the onsite GMP audits as soon as it becomes possible. Distant assessment and supplier qualification will certainly increase in the near future, but these qualifications cannot replace the onsite audit requirements.
Resources:
Notice to stakeholder’s questions and answers on regulatory expectations for medicinal products for human use during the covid-19 pandemic:
https://ec.europa.eu/health/sites/health/files/human-use/docs/guidance_regulatory_covid19_en.pdf
Donald Trump’s tariffs of 50% have come into force on most US imports from India. India’s giant generic pharmaceuticals sector and its electronics and petroleum products are exempt from the tariffs. Aluminium, steel and copper remain at 25%, but job-heavy sectors such as textiles, jewellery, seafood and leather are squarely in the line of fire.
The European Chemicals Agency (ECHA) has published the updated proposal to restrict per- and polyfluoroalkyl substances (PFAS) under the EU’s chemicals regulation, REACH. The update has been prepared by the authorities from Denmark, Germany, the Netherlands, Norway and Sweden, who submitted the initial proposal in January 2023.
Most chemicals exported from the 27 member countries of the European Union into the US will be subject to a 15% tariff on top of their selling prices under an agreement signed on July 27 between the US and the European Commission.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.